| DB ID | MyCo_7107 |
| Title | Kinetics of serum β-D-glucan after Pneumocystis pneumonia treatment in patients with AIDS |
| Year | 2011 |
| PMID | 21720059 |
| Fungal Diseases involved | Pneumocystis jirovecii pneumonia |
| Associated Medical Condition | HIV-AIDS |
| Genus | Pneumocystis |
| Species | jirovecii |
| Organism | Pneumocystis jirovecii |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Negative |
| Biomolecule | Protein |
| Geographical Location | Japan |
| Cohort | Seventeen PCP patients with AIDS who were admitted to our hospital were analyzed. |
| Cohort No. | 17 |
| Age Group | 25-61 |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pneumocystis pneumonia (PCP), caused by Pneumocystis jirovecii (P. jirovecii), is one of the most prevalent opportun-istic infections among individuals with impaired immunity, particularly in patients with acquired immune deficiency syndrome (AIDS). |
| Technique | Analytic |
| Analysis Method | Wako BDG test |
| ELISA kits | β-D-glucan Wako test Kit (Wako Pure Chemical Industries, Osaka, Japan). |
| Assay Data | None |
| Validation Techniques used | Wako BDG test |
| Up Regulation Down Regulation | Negative |
| Sequence Data | None |
| External Link | None |
